Roche: signs partnership with SpeeDx
(CercleFinance.com) - Roche and SpeeDx, a developer of innovative molecular diagnostic solutions, have signed a partnership deal to expand access to antibiotic resistance testing.
Under the terms of the agreement, Roche will gain non-exclusive access to SpeeDx's portfolio in order to expand its diagnostics products, in particular for sexually transmitted infections.
"Rising rates of antibiotic resistance are a serious global problem. New, technologically advanced diagnostics help clinicians choose the best targeted therapy for individual patients based on the resistance status of their infection," the group said.
"The agreement with SpeeDx will allow Roche Diagnostics to provide clinicians with important new tools for detecting antibiotic resistance in patients with sexually transmitted infections," said Mario Torres, Head of Roche Molecular Diagnostics.
Copyright (c) 2020 CercleFinance.com. All rights reserved.
Under the terms of the agreement, Roche will gain non-exclusive access to SpeeDx's portfolio in order to expand its diagnostics products, in particular for sexually transmitted infections.
"Rising rates of antibiotic resistance are a serious global problem. New, technologically advanced diagnostics help clinicians choose the best targeted therapy for individual patients based on the resistance status of their infection," the group said.
"The agreement with SpeeDx will allow Roche Diagnostics to provide clinicians with important new tools for detecting antibiotic resistance in patients with sexually transmitted infections," said Mario Torres, Head of Roche Molecular Diagnostics.
Copyright (c) 2020 CercleFinance.com. All rights reserved.